Búsqueda | Portal de Búsqueda de la BVS España

1.

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.

Chen, H; Modiano, M R; Neal, J W; Brahmer, J R; Rigas, J R; Jotte, R M; Leighl, N B; Riess, J W; Kuo, C J; Liu, L; Gao, B; Dicioccio, A T; Adjei, A A; Wakelee, H A.

Br J Cancer; 110(3): 602-8, 2014 Feb 04.

Artículo en Inglés | MEDLINE | ID: mdl-24292447

2.

Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.

Gauthier, I; Ding, K; Winton, T; Shepherd, F A; Livingston, R; Johnson, D H; Rigas, J R; Whitehead, M; Graham, B; Seymour, L.

Lung Cancer; 55(3): 357-63, 2007 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-17141357

3.

Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole.

Rigas, J R; Francis, P A; Muindi, J R; Kris, M G; Huselton, C; DeGrazia, F; Orazem, J P; Young, C W; Warrell, R P.

J Natl Cancer Inst; 85(23): 1921-6, 1993 Dec 01.

Artículo en Inglés | MEDLINE | ID: mdl-8230282

4.

Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans-retinoic acid in patients with advanced cancer.

Muindi, J F; Scher, H I; Rigas, J R; Warrell, R P; Young, C W.

Cancer Res; 54(8): 2125-8, 1994 Apr 15.

Artículo en Inglés | MEDLINE | ID: mdl-8174117

5.

Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.

Rigas, J R; Tong, W P; Kris, M G; Orazem, J P; Young, C W; Warrell, R P.

Cancer Res; 52(23): 6619-23, 1992 Dec 01.

Artículo en Inglés | MEDLINE | ID: mdl-1423306

6.

Metabolic phenotypes of retinoic acid and the risk of lung cancer.

Rigas, J R; Miller, V A; Zhang, Z F; Klimstra, D S; Tong, W P; Kris, M G; Warrell, R P.

Cancer Res; 56(12): 2692-6, 1996 Jun 15.

Artículo en Inglés | MEDLINE | ID: mdl-8665495

7.

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.

Francis, P A; Rigas, J R; Kris, M G; Pisters, K M; Orazem, J P; Woolley, K J; Heelan, R T.

J Clin Oncol; 12(6): 1232-7, 1994 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-7911159

8.

Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.

Khuri, F R; Rigas, J R; Figlin, R A; Gralla, R J; Shin, D M; Munden, R; Fox, N; Huyghe, M R; Kean, Y; Reich, S D; Hong, W K.

J Clin Oncol; 19(10): 2626-37, 2001 May 15.

Artículo en Inglés | MEDLINE | ID: mdl-11352954

9.

Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.

Miller, V A; Benedetti, F M; Rigas, J R; Verret, A L; Pfister, D G; Straus, D; Kris, M G; Crisp, M; Heyman, R; Loewen, G R; Truglia, J A; Warrell, R P.

J Clin Oncol; 15(2): 790-5, 1997 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-9053506

10.

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Bruno, R; Hille, D; Riva, A; Vivier, N; ten Bokkel Huinnink, W W; van Oosterom, A T; Kaye, S B; Verweij, J; Fossella, F V; Valero, V; Rigas, J R; Seidman, A D; Chevallier, B; Fumoleau, P; Burris, H A; Ravdin, P M; Sheiner, L B.

J Clin Oncol; 16(1): 187-96, 1998 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-9440742

11.

Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid.

Miller, V A; Rigas, J R; Benedetti, F M; Verret, A L; Tong, W P; Kris, M G; Gill, G M; Loewen, G R; Truglia, J A; Ulm, E H; Warrell, R P.

Clin Cancer Res; 2(3): 471-5, 1996 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-9816192

12.

High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.

Pisters, K M; Tyson, L B; Tong, W; Fleisher, M; Miller, V A; Grant, S C; Pfister, D G; Rigas, J R; Densmore, C L; Krol, G; Heelan, R T; Sirotnak, F M; Bertino, J R; Kris, M G.

Clin Cancer Res; 2(11): 1819-24, 1996 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-9816135

13.

Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results.

Rathmann, J; Leopold, K A; Rigas, J R.

Semin Radiat Oncol; 9(2 Suppl 1): 130-5, 1999 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-10210552

14.

Docetaxel in stage III and IV non-small cell lung cancer.

Rigas, J R.

Eur J Cancer; 31A Suppl 4: S18-20, 1995.

Artículo en Inglés | MEDLINE | ID: mdl-7577100

15.

Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?

Rigas, J R.

Semin Oncol; 25(3 Suppl 8): 5-9, 1998 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-9704669

16.

Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.

Rigas, J R.

Semin Oncol; 28(3 Suppl 9): 15-20, 2001 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-11441410

17.

A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum.

Bengtson, E M; Rigas, J R.

Semin Oncol; 26(5 Suppl 16): 1-6, 1999 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-10585002

18.

Modulation of apoptosis signaling pathways and cell cycle regulation.

Eastman, A; Rigas, J R.

Semin Oncol; 26(5 Suppl 16): 7-16; discussion 41-2, 1999 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-10585003

19.

The future beyond platinum for the treatment of advanced non-small cell lung cancer.

Dragnev, K H; Rigas, J R.

Semin Oncol; 26(5 Suppl 16): 73-6, 1999 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-10585012

20.

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.

Shepherd, F A; Fossella, F V; Lynch, T; Armand, J P; Rigas, J R; Kris, M G.

Semin Oncol; 28(1 Suppl 2): 4-9, 2001 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-11284623

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.

Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.

Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole.

Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans-retinoic acid in patients with advanced cancer.

Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.

Metabolic phenotypes of retinoic acid and the risk of lung cancer.

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.

Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.

Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid.

High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.

Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results.

Docetaxel in stage III and IV non-small cell lung cancer.

Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?

Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.

A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum.

Modulation of apoptosis signaling pathways and cell cycle regulation.

The future beyond platinum for the treatment of advanced non-small cell lung cancer.

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.